Onconetix, Inc.
Current role
ONCO
Ralph Schiess
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Ralph Schiess
Onconetix, Inc. reported in an 8-K filed December 21, 2023 that Ralph Schiess was appointed Chief Science Officer, effective December 15, 2023. The proxy statement of Onconetix, Inc. reports total compensation of $305,176 for Ralph Schiess in fiscal 2024, including a base salary of $265,176. Disclosed compensation is on record for 2 fiscal years.
“On December 15, 2023, Onconetix appointed Ralph Schiess, 45, as Chief Science Officer of Onconetix, effective immediately, to serve until the election and qualification of his successor or his earlier death, resignation, or removal.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Onconetix, Inc. (ONCO)
SEC 8-K
Current2023-12-15–present
-
Start not stated–2025-02-24
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Onconetix, Inc.
Other people whose current roles at this company are on record from its filings.
- David White CEO
- Dr. Ralph Schiess CEO
- Jon Garfield CEO
- Neil Campbell CEO, Board Member
- Neil J. Campbell CEO, Board Member
- James Sapirstein Chairman, Board Member
- Sammy Dorf Chairman, Board Member
- Bruce Harmon CFO
- Karina Fedasz CFO
- Ajit Singh Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Onconetix, Inc. (ONCO) | Former Interim Chief Executive Officer and Former Chief Science Officer | $265,176 | $305,176 |
| 2023 | Onconetix, Inc. (ONCO) | Former Interim Chief Executive Officer and Former Chief Science Officer | $11,228 | $105,545 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.